Sai Life Sciences cash flow

Latest FY26
Cash from operations
₹509cr+62.1% on FY25
Capital spending
₹593cr+60.6% on FY25
Free cash flow
−₹83.8cr−₹55.2 cr in FY25
Cash from financing
−₹124cr₹301 cr in FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—167139
—39.276.2
—−18.6−17.6
—2.12.5
—−9.55.0
—−24.434.4
Changes in working capital
—−32.1−31.4
—−15.4−100.0
—−13.12.4
—−102−158
—−3.22.2
—32.7106
—0.06.3
—0.041.5
—44.50.0
—14.80.0
Cash from operating activities
483466228
—81.9108
—548336
—38.921.6
—509314
Cash from investing activities
—593369
—0.50.0
—0.00.5
—1.60.0
—0.00.1
—22.515.9
—176−184
—−395−537
Cash from financing activities
—5.21,000
—25.553.4
—58.9624
—84.876.0
—10.852.5
—−124301
—−10.078.8
—0.80.3
—−9.179.1
Reference items
658631406
29.3%28.8%23.9%
−83.8−83.8−55.2
—−128—
−₹3.96−₹3.96−₹2.61
—1.46×1.85×
—38.921.6
—10.852.5
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SAILIFE₹1,495.70

Sai Life Sciences Ltd.

· Pharma & Health
₹ CrorePeersSYNGENEDIVISLABPPLPHARMANHNEULANDLABNATCOPHARMLALPATHLABCOHANCEMcap ₹31,676 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation138.6166.9—
+ Finance Costs76.239.2—
+ Interest Income-17.6-18.6—
+ Share-based Payments2.52.1—
+ Unrealised FX (Gain) / Loss5.0-9.5—
+ Other Non-cash Items34.4-24.4—
Changes in Working Capital
+ Inventories-31.4-32.1—
+ Trade Receivables — Current-100.0-15.4—
+ Other Financial Assets — Non-current2.4-13.1—
+ Other Current Assets-157.9-102.0—
+ Other Non-current Assets2.2-3.2—
+ Trade Payables — Current105.932.7—
+ Other Financial Liabilities — Current6.30.0—
+ Other Financial Liabilities — Non-current41.50.0—
+ Other Current Liabilities0.044.5—
+ Other Non-current Liabilities0.014.8—
Cash from Operating Activities
Profit Before Tax (per I/S)227.7466.2483.4
+ Total Adjustments (incl. Working Capital)108.081.9—
Cash from Operations (pre-tax)335.7548.1—
+ Income Taxes Paid21.638.9—
Cash from Operating Activities314.0509.1—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)369.3593.0—
+ Disp of Fixed Assets0.00.5—
+ Disp of Investment Property0.50.0—
+ Purchase of Investments (Equity / Debt)0.01.6—
+ Acq of Subsidiaries / Businesses (net)0.10.0—
+ Interest Received — Investing15.922.5—
+ Other Inflows / (Outflows) — Investing-183.7176.1—
Cash from Investing Activities-536.7-395.4—
Cash from Financing Activities
+ Proceeds from Issue of Shares1,000.35.2—
+ Proceeds from Borrowings53.425.5—
+ Repayment of Borrowings623.858.9—
+ Payment of Lease Liabilities76.084.8—
+ Interest Paid52.510.8—
Cash from Financing Activities301.4-123.7—
Net Changes in Cash (pre-FX)78.8-10.0—
+ Effect of FX Rate Changes on Cash0.30.8—
Net Changes in Cash79.1-9.1—
Reference Items
EBITDA405.7631.2658.2
EBITDA Margin %23.9428.7929.25
Free Cash Flow (CFO − Capex)-55.2-83.8-83.8
Free Cash Flow to Equity—-128.1—
Free Cash Flow per Basic Share-2.61-3.96-3.96
Cash Flow to Net Income1.851.46—
Cash Paid for Taxes21.638.9—
Cash Paid for Interest52.510.8—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.